Nivolumab combined with AVD demonstrated superior progression-free survival compared with brentuximab vedotin with AVD in advanced classical Hodgkin lymphoma (cHL). The SWOG S1826 trial showed a ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
1 Laboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil 2 Laboratory Human Molecular Genetics, ...
NEW YORK, Nov 12 (Reuters) - The U.S. Food and Drug Administration can approve new personalized treatments for rare and deadly genetic diseases based on data from a handful of patients, two of the ...
– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...
SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...
Bye Sweet Carole is an indie puzzle-platformer game that follows Lana Benton as she searches for her missing best friend, Carole Simmons. This exquisite, completely hand-drawn animated game is an ...
The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
Health tech company Doximity bought Pathway Medical to bulk up its healthcare artificial intelligence capabilities as it looks to offer more free AI tools to doctors. The transaction closed July 29 ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results